TMO (STOCKS)
Thermo Fisher Scientific, Inc.
$477.000000
+7.660000 (+1.63%)
Prev close: $469.340000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Marc N. Casper
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $176,096.54M
- Employees
- 125,000
- P/E (TTM)
- 25.80
- P/B (TTM)
- 3.36
- Dividend Yield
- 37.50%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
18
Buy
5
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$5.44 | $5.29 | +0.1504 | +2.84% |
|
Dec 2025 (Q4)
|
$6.57 | $6.51 | +0.0594 | +0.91% |
|
Sep 2025 (Q3)
|
$5.79 | $5.55 | +0.2422 | +4.37% |
|
Jun 2025 (Q2)
|
$5.36 | $5.28 | +0.0847 | +1.61% |
Financial Statements
| Revenues | $45.20B |
| Benefits Costs and Expenses | $37.78B |
| Costs And Expenses | $37.31B |
| Operating Expenses | $37.30B |
| Selling, General, and Administrative Expenses | $8.84B |
| Research and Development | $1.39B |
| Other Operating Expenses | $27.08B |
| Operating Income/Loss | $7.89B |
| Income/Loss Before Equity Method Investments | $7.42B |
| Income/Loss From Continuing Operations After Tax | $6.90B |
| Income/Loss From Continuing Operations Before Tax | $7.42B |
| Income/Loss From Equity Method Investments | -$36.00M |
| Income Tax Expense/Benefit | $522.00M |
| Income Tax Expense/Benefit, Deferred | -$618.00M |
| Net Income/Loss | $6.87B |
| Net Income/Loss Attributable To Noncontrolling Interest | $18.00M |
| Net Income/Loss Attributable To Parent | $6.85B |
| Net Income/Loss Attributable To Redeemable Noncontrolling Interest | $26.00M |
| Net Income/Loss Available To Common Stockholders, Basic | $6.85B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $18.22 |
| Diluted Earnings Per Share | $18.19 |
| Basic Average Shares | 1,127,000,000 |
| Diluted Average Shares | 1,129,000,000 |
| Assets | $113.28B |
| Current Assets | $22.32B |
| Inventory | $5.50B |
| Other Current Assets | $16.82B |
| Noncurrent Assets | $90.97B |
| Fixed Assets | $10.66B |
| Intangible Assets | $19.15B |
| Other Non-current Assets | $61.16B |
| Liabilities | $61.34B |
| Current Liabilities | $14.62B |
| Accounts Payable | $3.34B |
| Wages | $1.57B |
| Other Current Liabilities | $9.71B |
| Noncurrent Liabilities | $46.72B |
| Long-term Debt | $42.95B |
| Other Non-current Liabilities | $3.77B |
| Redeemable Noncontrolling Interest | $121.00M |
| Equity | $51.94B |
| Equity Attributable To Noncontrolling Interest | $7.00M |
| Equity Attributable To Parent | $51.93B |
| Temporary Equity | $121.00M |
| Liabilities And Equity | $113.28B |
| Net Cash Flow From Operating Activities | $8.29B |
| Net Cash Flow From Operating Activities, Continuing | $8.29B |
| Net Cash Flow From Investing Activities | -$12.48B |
| Net Cash Flow From Investing Activities, Continuing | -$12.48B |
| Net Cash Flow From Financing Activities | $3.00B |
| Net Cash Flow From Financing Activities, Continuing | $3.00B |
| Net Cash Flow | -$1.20B |
| Net Cash Flow, Continuing | -$1.20B |
| Comprehensive Income/Loss | $6.70B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $8.00M |
| Comprehensive Income/Loss Attributable To Parent | $6.69B |
| Other Comprehensive Income/Loss | -$163.00M |